All In Biotech

Drug Trial Radar · NCT07511816

A Study of LY4515100 in Participants With Pain Following Third Molar Removal

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of a Single Oral Dose of LY4515100, in Participants Experiencing Moderate-to-Severe Acute Pain Following Surgical Removal of Impacted Third Molars

Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 212 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

212

Planned (sponsor's estimate)

Start

Apr 1, 2026

Primary completion

Nov 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Apr 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of LY4515100 and see how a single oral dose compares with placebo in acute postsurgical pain after removing impacted third molars. For each participant, the study may last approximately 6 weeks and will include a stay in a Clinical Research Unit (CRU) after third molar removal.

Conditions

  • Acute Pain
  • Molar
  • Molar, Third
  • Surgery, Oral

Interventions

  • LY4515100Drug

    Administered Orally

  • PlaceboDrug

    Administered Orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Self-Reported Pain IntensityTime frame: Baseline, Up to Day 1

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • JBR Clinical Research

    Salt Lake City, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.